In the lab, whether we are studying tissues or managing data, we are thinking of the patient whose life will be bettered by the research we conduct. As one of the most successful oral and maxillofacial surgery/ hospital dentistry units in the country in securing external funding, we bring deep resources and diverse skills to bear on solving the most vexing surgical dilemmas.

Discovering the Future of Oral & Maxillofacial Surgery/Hospital Dentistry

Our dedicated research labs, include a microsurgical training lab, as well as basic and translational scientific labs. All our faculty conduct research, a demonstration of our commitment to generating new knowledge, with one faculty member devoting 60 percent of his time to research — a unique position that broadens our understanding of the intersection of basic science and clinical practice.

Our investigators are recognized leaders in the field, and have served as chairs of multiple national and international committees. We are also chairs of research interest groups in oncology, reconstruction, and craniofacial surgery and biotechnology advisor boards and foundations in addition to a UM spin-off biotechnology company, Tissue Regeneration Systems.

Our research efforts range from wet laboratory basic research to randomized prospective clinical trials, a case-control observational study, and a national database in oncology.

Current research interests include:

  • Oral health-related cardiovascular effects, including investigation of the impact of oral hygiene and periodontal disease on the association with community-acquired infective endocarditis. 
  • Tissue engineering/Regenerative medicine, including the development of engineered tissue for intraoral grafting to treat facial disfigurement in patients in need of oral tissue.
  • Cell-based therapeutics, including the development of an osteo-inductive coating for biodegradable scaffolds for use with bone tissue engineering.
  • Novel TMJ treatments, including investigation of maxillomandibular advancement for patients who are refractory to CPAP; as well as the use of botulinum toxin A in the treatment of myofascial pain associated with TMJ dysfunction.
  • Optimization of cancer care through evidenced based data driven personalized patient decisions.